Two Sigma Investments
ARTV

Two Sigma Investments’s Artiva Biotherapeutics ARTV Stock Holding History

Two Sigma Investments’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$741K Sell
115,041
-29,823
-21% -$148K ﹤0.01% 3460
2025
Q4 		$621K Buy
144,864
+124,500
+611% +$470K ﹤0.01% 3195
2025
Q3 		$58.4K Sell
20,364
-1,007
-5% -$2.69K ﹤0.01% 3527
2025
Q2 		$32.3K Buy
+21,371
New +$44.9K ﹤0.01% 3097

Other funds holding ARTV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RCM
Revelation Capital Management Sausalito, California $67.4M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

Two Sigma Investments's ARTV Position: Q1 2026 in Review

Two Sigma Investments reduced its Artiva Biotherapeutics (ARTV) stake by 21% in Q1 2026, selling an estimated $148K and leaving 115,041 shares worth $741K. The position accounts for ﹤0.01% of the portfolio, ranked #3460.

Two Sigma Investments first reported a position in ARTV in Q2 2025 and has held it in 4 quarters since. 40 funds tracked by Wall St. Rank hold ARTV as of Q1 2026.

  • Two Sigma Investments held 115,041 shares of Artiva Biotherapeutics worth $741K as of Q1 2026.
  • Two Sigma Investments sold 29,823 Artiva Biotherapeutics shares in Q1 2026, an estimated $148K.
  • Artiva Biotherapeutics made up ﹤0.01% of Two Sigma Investments's portfolio in Q1 2026, its #3460 holding.
  • Two Sigma Investments first reported a position in Artiva Biotherapeutics in Q2 2025 and has held it in 4 quarters since.
  • 40 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q1 2026.

Based on Two Sigma Investments's 13F filing for Q1 2026, filed 15 May 2026.